Mark Lanasa: Great news for patients in the U.S. with advanced esophageal squamous cell carcinoma
Mark Lanasa, Chief Medical Officer of Solid Tumors at BeiGene, shared a post by BeiGene on LinkedIn, adding:
“Great news for patients in the U.S. with advanced esophageal squamous cell carcinoma (ESCC). Our team’s dedication to advancing cancer care has led to another important milestone – FDA approval of our PD-1 inhibitor + chemotherapy for first-line treatment in patients whose tumors express PD-L1 (≥1).
This is a significant step in addressing a rapidly fatal disease, and I’m proud to be part of a team committed to bringing innovative therapies to those who need them most.”
Quoting BeiGene‘s post:
“News for Investors and Media: The U.S. FDA has approved our PD-1 inhibitor, in combination with chemotherapy, for the first-line treatment of advanced esophageal squamous cell carcinoma (ESCC) in adults whose tumors express PD-L1 (≥1).
Esophageal cancer is a rapidly fatal disease, and more than two-thirds of patients have advanced or metastatic disease at the time of diagnosis. This approval, the third for our PD-1 inhibitor from the FDA, reflects our dedication to advancing innovative therapies and addressing critical needs in cancer care.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023